PAVmed's (PAVM) Lucid Diagnostics Files For a Proposed IPO
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/18/2026
- Wall Street tumbles as worries about AI trade and high oil prices weigh
- Oil touches $110 a barrel for first time since May on Middle East, Russia supply fears
- Stay risk-off as higher real yields and AI volatility threaten stocks: BofA
- Appleās first foldable iPhone sells out within minutes as preorders begin
- CoreWeave bond rout tests market's math on AI buildout
- Yorkville Ives: 'GameStop Is Becoming the Hobby's Intake Network'
- Wall Street tumbles as worries about AI trade and high oil prices weigh
- Micron Technology stock drops on China chip news and labor dispute
- Truist Financial to sell $7.7B LightStream loan portfolio to Carlyle
- Truist Financial to sell $7.7B LightStream loan portfolio to Carlyle
PAVmed Subsidiary, Lucid Diagnostics, Files Registration Statement for Proposed Initial Public Offering
September 23, 2021 9:30 AM EDTNEW YORK--(BUSINESS WIRE)-- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (PAVmed), a highly differentiated, multi-product, commercial-stage medical technology company, and its majority-owned subsidiary, Lucid Diagnostics Inc. (Lucid), announced yesterday that Lucid has publicly filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (the SEC) relating to the proposed initial public offering of its common stock. The number of shares to be offered and the price range for the offering have not yet been determined. Lucid Diagnostics intends to list its common stock on The Nasdaq Stock Market under the ticker symbol "LUCD.
Cantor Fitzgerald & Co.... More



